Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **Industry**: Biotechnology, specifically focusing on oral therapeutics in the Inflammatory and Immune (I&I) space - **Lead Drug**: PALI-2108, a PDE4 inhibitor developed for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis [2][3] Core Points and Arguments - **Drug Development Background**: - PALI-2108 was originally developed by Merck and later reformulated as a prodrug by Giiant Pharma [2] - The prodrug formulation is crucial as it mitigates severe adverse events associated with traditional PDE4 inhibitors, such as secretory diarrhea and CNS events [3][4] - **Clinical Development Status**: - Completed preclinical development and initiated clinical trials, treating 84 healthy volunteers and 5 ulcerative colitis patients [4][5] - Currently conducting a small cohort study in fibrostenotic Crohn's disease, with results expected by the end of the month [5] - Plans to file an IND for a definitive study in ulcerative colitis involving 196 patients by May, with patient treatment starting in early Q3 2026 and data readout by the end of 2027 [5][13] - **Market Potential**: - Crohn's disease and ulcerative colitis are multi-billion dollar markets, with fibrostenotic Crohn's disease being a significant unmet need as there are currently no approved therapies [14] - The company aims to differentiate itself with a dual-acting anti-inflammatory and anti-fibrotic drug, which is unique in the market [11][19] - **Competitive Landscape**: - Competitors include Agomab, which recently IPO'd at over $750 million, and other PDE4 inhibitors like AstraZeneca's roflumilast and Amgen's Otezla [12][14] - The company has developed a precision medicine test to identify potential responders to PALI-2108 [12] - **Efficacy and Safety Data**: - Early data from a phase 1B study showed promising results, including a 63% improvement in the modified Mayo score and significant reductions in inflammatory markers after just one week of treatment [24][42] - The drug demonstrated good safety and tolerability, with no serious adverse events reported even at high doses [44][45] Additional Important Content - **Financial Position**: - Completed a financing round in October 2025, providing sufficient funds to support definitive studies in both ulcerative colitis and fibrostenotic Crohn's disease, with a runway extending into 2029 [30][31] - **Team and Expertise**: - The company has built a strong team with experience from major pharmaceutical companies, enhancing its capability to execute its development plans [32] - **Regulatory Considerations**: - The company is evaluating whether to pursue a broader indication for Crohn's disease or focus specifically on fibrosing Crohn's, depending on the data from ongoing studies [33][34] - **Market Positioning**: - The company aims to position PALI-2108 as a faster-acting oral option in a market currently dominated by injectable therapies with lower remission rates [40][41] - **Long-term Durability of Response**: - The company is confident in the long-term efficacy of PALI-2108 based on historical data from other PDE4 inhibitors and ongoing studies [42][43] This summary encapsulates the key points discussed during the Palisade Bio FY Conference Call, highlighting the company's strategic direction, clinical development progress, market potential, and competitive landscape.

Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **Industry**: Biotechnology, specifically focusing on oral therapeutics in the Inflammatory & Immune (I&I) space - **Lead Drug**: PALI-2108, a PDE4 inhibitor developed for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis [2][3] Core Points and Arguments Drug Development and Mechanism - PALI-2108 is a prodrug formulation that releases its active ingredient in the lower gastrointestinal (GI) tract, avoiding adverse events associated with traditional PDE4 inhibitors, such as secretory diarrhea and CNS events like headache and nausea [3][4] - The drug has shown efficacy in treating IBD diseases, with a focus on reducing adverse events by localizing the drug's action [3][4] Clinical Trials and Milestones - Completed preclinical development and initiated clinical trials, treating 84 healthy volunteers and 5 ulcerative colitis patients in a Phase 1b cohort [4][5] - A small cohort study in fibrostenotic Crohn's disease is expected to read out by the end of March 2026 [5] - Plans to file an Investigational New Drug (IND) application for ulcerative colitis in May 2026, with patient treatment starting in early Q3 2026 and data readout by the end of 2027 [5][13] Market Potential - Crohn's disease and ulcerative colitis are identified as multi-billion dollar markets, with fibrostenotic Crohn's disease being a significant unmet need as there are currently no approved therapies [14] - The company aims to differentiate itself by being the first dual-acting anti-inflammatory and anti-fibrotic drug in development for fibrostenotic Crohn's disease [11][14] Competitive Landscape - Competitors include Agomab, which recently IPO'd at over $750 million, and other PDE4 inhibitors like AstraZeneca's roflumilast and Amgen's Otezla [12][14] - The company is developing a precision medicine test to identify potential responders to PALI-2108, enhancing its competitive edge [12][19] Financial Overview - Completed a transformational financing in October 2025, providing sufficient funds to support definitive studies in both ulcerative colitis and fibrostenotic Crohn's disease, with a runway extending into 2029 [28][29] - The company maintains a clean capital structure with 206 million shares fully diluted [28][29] Key Insights and Considerations - The drug's design aims to minimize common PDE4-related adverse events, which could enhance its market acceptance [43][44] - The company emphasizes its capital efficiency and execution capabilities, which may be underappreciated in the market [47][48] - There is ongoing evaluation regarding whether to pursue a broader indication for Crohn's disease or focus specifically on fibrosing Crohn's, pending data from the Phase 1b cohort [31][33] Conclusion Palisade Bio is positioned in a promising niche within the biotechnology sector, focusing on innovative oral therapeutics for IBD. The company's strategic development of PALI-2108, along with its financial backing and market potential, presents a compelling case for investors looking for opportunities in the healthcare space.

Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **History**: Established approximately 16 years ago, with a significant transformation occurring in summer 2023 after a phase 2 study yielded disappointing results. The company pivoted to focus on a PDE4 inhibitor acquired from Giiant Pharma, which was originally developed in Merck labs in Montreal [4][5]. Core Product and Mechanism - **Product**: PALI-2108, a prodrug PDE4 inhibitor designed to mitigate common adverse effects associated with traditional PDE4 inhibitors, such as diarrhea, headache, and nausea [7][9]. - **Mechanism**: The prodrug formulation allows for gut-restricted action, releasing the active ingredient in the distal gut, thus avoiding upper gastrointestinal issues. It has a long half-life and is administered once daily, which is unique among PDE4 inhibitors [10][11][12]. Clinical Development - **Phase 1A and 1B Studies**: Completed with promising results, including a 63% improvement in modified Mayo score in a small open-label study of 5 ulcerative colitis (UC) patients [18]. - **Phase II Plans**: Enrollment for the Phase II UC study is expected to start in Q3 2026, with top-line results anticipated by the end of 2027. The study aims to include 50-70% bio-experienced patients [23][39]. Market Opportunity - **Fibrostenosing Crohn's Disease (FSCD)**: Identified as a significant unmet need, with 75% of Crohn's patients requiring surgery for strictures. There are approximately 200,000 symptomatic patients in the U.S. alone [27]. - **Potential for Broader Applications**: The drug's mechanism may also be applicable to other inflammatory conditions, including COPD and IPF, due to its improved pharmacology and tolerability [43]. Financial Position - **Funding**: The company raised $138 million in a re-IPO, providing sufficient runway to conduct definitive studies in UC and Crohn's, with cash expected to last into 2029 [40]. Strategic Considerations - **Corporate Development**: The company is in early discussions with large pharmaceutical firms to raise awareness of its developments, preparing for potential partnerships as data becomes available [45]. Key Takeaways - **Innovative Approach**: PALI-2108's prodrug formulation represents a significant advancement in the treatment of inflammatory bowel diseases, aiming to improve patient tolerability and outcomes. - **Strong Pipeline**: The company is strategically positioned to address significant unmet needs in both UC and Crohn's disease, with plans for future studies and potential expansion into other therapeutic areas. - **Robust Financial Backing**: The recent funding provides a solid foundation for ongoing clinical trials and development efforts, enhancing the company's prospects for success in the competitive biotech landscape.